MUSC Hollings Cancer Center Opens Dedicated Clinical Cancer Trials Unit
In a notable leap toward innovative cancer treatment, MUSC Hollings Cancer Center opened its first dedicated clinical cancer research unit, the Summer and Clyde Anderson Advanced Cancer Therapy Clinic. The opening follows five years of meticulous planning. This groundbreaking clinic will provide specialized treatment to patients participating in phase I clinical trials for cancer.
Expanding Capabilities and Improving Cancer Care
This new facility will significantly enhance Hollings’ capabilities to offer patients more and varied types of clinical trials that previously posed logistical challenges. Moreover, this venture ensures that promising newly approved treatments by the Food and Drug Administration (FDA) are not foreign to the Hollings team, as they would likely have already administered such treatments during clinical trials before FDA approval.
Raymond N. DuBois, M.D., Ph.D., the director of Hollings, expressed that this new unit embodies their commitment to offering the most cutting-edge clinical trials. He further stated, “Clinical trials are how we improve cancer care for everyone, and clinical trials are a lifeline for the individual patients who choose to participate.”
A Tailored Space for Advanced Care
The Anderson Advanced Cancer Therapy Clinic, a tranquil oasis of sunlight and calm, includes every facility necessary for phase I trials. It features spacious infusion areas and a dedicated team of experienced nurses particularly trained in chemotherapy, immunotherapy infusion, and clinical trial protocols.
“One of the biggest benefits is the way that we’ve been able to elevate the care that these patients are receiving,” said Sierra Baker, R.N., the nurse manager for the Anderson Clinic.
The Importance of Clinical Trials
Phase I clinical trials primarily focus on evaluating drug safety, optimal dosage, timing, and potential side effects. Clinical trials are the first step towards testing new drugs or assessing specific combinations of already approved drugs in humans. Hence, these trials offer patients the chance of receiving a therapy that could soon be considered as standard practice.
John Kaczmar, M.D., a head and neck cancer oncologist who leads the unit, expressed enthusiasm towards this venture. He highlighted the Clinic’s immense potential in improving cancer care. “The Anderson Clinic is a game-changer in so many ways. It’s a forward-thinking, functional, and inviting space that allows for dynamic patient care and improved patient comfort during therapy,” he said.
A Step Towards a Brighter Future
The team at the Hollings Clinical Trials Office sees this development as advantageous for all patients, even those who may not participate in a clinical trial. Tricia Adrales Bentz, administrative director of the office, explained – “Through the process of doing these research studies, our Hollings clinicians have gained expertise in the latest breakthroughs before anyone else.”
This new research unit signifies a significant step in improving cancer outcomes, taking the outstanding research facility to the next level. Recognizing the immense potential that lies ahead, the team anticipates celebrating the new unit once the lobby renovations have been completed.
